FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)

• Revolution Medicines announced that the FDA has accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma, supported by the positive Phase 3 RASolute 302 trial showing improved survival, progression-free survival and quality of life versus standard chemotherapy.
• The therapy’s inclusion in multiple high-priority U.S. and European regulatory programs, including the FDA Commissioner’s National Priority Voucher pilot, highlights daraxonrasib’s potential to address a major unmet need in pancreatic cancer care.
• We’ll explore how daraxonrasib’s successful Phase 3 data and priority FDA review could reshape Revolution Medicines’ investment narrative and future catalysts.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Revolution Medicines Investment Narrative Recap

To own Revolution Medicines, you need to believe its RAS(ON) platform can turn today’s losses and cash burn into approved therapies across several major cancers. The FDA’s acceptance of daraxonrasib’s NDA in metastatic pancreatic cancer reinforces the core thesis and likely becomes the most important near term catalyst, while the key risk remains the company’s heavy spending and lack of current revenue as it builds a commercial organization ahead of any product launches.

The upcoming second quarter 2026 earnings update on August 5 sits in the shadow of the daraxonrasib filing, but it still matters for the story. With no product revenue and a Q1 2026 net loss of US$453.82 million, investors will be watching how fast operating expenses are ramping relative to the progress of late stage programs like daraxonrasib, as this balance could influence both future funding needs and the perceived durability of the pipeline.

Yet behind the excitement around daraxonrasib, investors should be aware that the company’s rapid expense growth and continuing net losses could...

Read the full narrative on Revolution Medicines (it's free!)

Revolution Medicines' narrative projects $2.3 billion revenue and $402.5 million earnings by 2029. This requires revenue to grow from zero and an earnings increase of about $1.8 billion from -$1.4 billion today.

Uncover how Revolution Medicines' forecasts yield a $204.38 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Before this news, the most pessimistic analysts expected only about US$838.8 million of revenue by 2029 and still no profits, so your view on whether RAS programs convert into meaningful earnings could differ sharply from theirs and may evolve as the daraxonrasib story and other late stage trials unfold.

Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Revolution Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com